Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Holding KPRX?
Track your performance easily

Kiora Pharmaceuticals (KPRX) Income Statement

417 Followers

Kiora Pharmaceuticals Income Statement

Last quarter (Q2 2024), Kiora Pharmaceuticals's total revenue was $20.00K, an increase of Infinity% from the same quarter last year. In Q2, Kiora Pharmaceuticals's net income was $-2.22M. See Kiora Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 16.02M---$ 12.06K$ 2.69M
Cost of Revenue
------
Gross Profit
$ 16.02M-----
Operating Expense
$ 13.89M$ 8.69M$ -12.31M$ 16.94M$ 8.22M$ 9.80M
Operating Income
$ 2.41M$ -12.59M$ -11.73M$ -10.67M$ -8.21M$ -7.11M
Net Non Operating Interest Income Expense
$ 660.15K$ 162.86K$ 48.29K$ -5.71K$ 19.15K$ 107.74K
Other Income Expense
$ -14.08M$ -3.90M$ 2.00M$ 1.52M$ 113.72K-
Pretax Income
$ 5.64M$ -12.42M$ -13.70M$ -16.70M$ -8.08M$ -7.00M
Tax Provision
-$ 90.32K$ -113.01K$ -304.78K$ 12.05K$ 95.40K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 2.32M$ -13.04M$ -13.58M$ -16.39M$ -8.09M$ -7.10M
Basic EPS
$ -1.69$ -2.69$ -18.55$ -1.77$ -1.77$ -2.23
Diluted EPS
$ -1.83$ -2.69$ -18.55$ -1.77$ -1.77$ -2.23
Basic Average Shares
$ 40.50M$ 4.84M$ 732.30K$ 9.24M$ 4.58M$ 3.18M
Diluted Average Shares
$ 49.59M$ 4.84M$ 732.30K$ 9.24M$ 4.58M$ 3.18M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 13.89M$ 8.69M$ -12.31M$ 16.94M$ 8.22M$ 9.80M
Net Income From Continuing And Discontinued Operation
$ 2.85M$ -12.51M$ -13.58M$ -16.39M$ -8.09M$ -7.10M
Normalized Income
$ -2.56M---$ -8.17M$ -7.10M
Interest Expense
----$ 4.19K$ 325.00
EBIT
$ 6.14M$ -12.95M$ -13.69M-$ -8.08M$ -7.00M
EBITDA
$ 8.53M$ -12.89M$ -13.65M-$ -8.04M$ -6.95M
Currency in USD

Kiora Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis